T. Lauterbach

发表

Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls.

Ulrike E. Hille, Qingzhong Hu, Carsten A. Vock, 2009, European journal of medicinal chemistry.

Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge.

Qingzhong Hu, M. Negri, M. Bartels, 2008, Bioorganic & medicinal chemistry.

Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.

M. Negri, U. Müller-Vieira, T. Lauterbach, 2008, Journal of medicinal chemistry.

A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial‐onset seizures in daily clinical practice: The VITOBA study

T. Mayer, T. Lauterbach, C. Brandt, 2015, Epilepsia.

Effectiveness and tolerability of rotigotine transdermal patch for the treatment of restless legs syndrome in a routine clinical practice setting in Germany.

T. Lauterbach, K. Stiasny‐Kolster, W. Hofmann, 2013, Sleep medicine.

Lacosamide added to a baseline monotherapy in patients with partial-onset seizures (POS): efficacy and safety across center types in the VITOBA study (P4.266)

T. Mayer, T. Lauterbach, C. Brandt, 2015 .

Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure.

Maurizio Recanatini, Andrea Cavalli, Thomas Lauterbach, 2008, Bioorganic & medicinal chemistry.

Changes in drug load during lacosamide combination therapy: A noninterventional, observational study in German and Austrian clinical practice

T. Mayer, T. Lauterbach, M. De Backer, 2019, Epilepsia open.

Caregivers’ and physicians’ attitudes to rotigotine transdermal patch versus oral Parkinson’s disease medication: an observational study

S. Lorenzl, T. Lauterbach, T. Warnecke, 2015, Current medical research and opinion.

Steroidogenic cytochrome P450 (CYP) enzymes as drug targets: Combining substructures of known CYP inhibitors leads to compounds with different inhibitory profile

Ulrike E. Hille, Qingzhong Hu, Carsten A. Vock, 2009 .

Reduction of gastrointestinal symptoms in Parkinson's disease after a switch from oral therapy to rotigotine transdermal patch: a non-interventional prospective multicenter trial.

L. Timmermann, T. Lauterbach, J. Kassubek, 2015, Parkinsonism & related disorders.

Patients’ perception of Parkinson’s disease-associated pain following initiation of rotigotine: a multicenter non-interventional study

L. Timmermann, T. Lauterbach, J. Kassubek, 2017, Postgraduate medicine.

CYP17 Inhibitors. Annulations of Additional Rings in Methylene Imidazole Substituted Biphenyls: Synthesis, Biological Evaluation and Molecular Modelling

Ulrike E. Hille, Qingzhong Hu, M. Negri, 2008, Archiv der Pharmazie.